title: [Scleroderma: an update on the pathogenesis and treatment].
abstract: Scleroderma is a multiorganic disease characterized by inflammatory, vascular and sclerotic changes in skin and internal organs. It is considered as a tripartite disease, associated to autoimmune, fibroblast and endothelial defect, due to genetic, environmental and infectious factors. This disease can be classified in systemic and localized form. The Raynaud phenomenon occurs in 90% of the patients with the diagnosis. It explains the microcirculation involvement and the reduction in the number of capillaries. Malformation of nail bed capillaries is readily demonstrated by nail bed microscopy and has been shown to correlate both with disease severity and with degree of internal organ involvement. The MRSS-51 validates the skin involvement and has the main predictive value to determine the patient survival. MRSS-51 should not be considered as an activity disease parameter or used to validate the effectiveness of treatment. Nowadays, multiple treatment alternatives exist for scleroderma disease; however these treatments offer poor results for the cutaneous manifestations.
authors.affiliation: Servicio de Dermatología, Hospital Universitario "Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, México. verogarzardz@hotmail.com
authors.forename: Verónica
authors.initials: V
authors.lastname: Garza-Rodríguez
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Villarreal-Alarcón
authors.forename: Jorge
authors.initials: J
authors.lastname: Ocampo-Candiani
mesh_terms: D006801:Humans; D012594:Scleroderma, Localized / Q000209:etiology* / Q000628:therapy*; D012595:Scleroderma, Systemic / Q000209:etiology* / Q000628:therapy*